Ascendis Pharma Endocrinology Division A/S — Credit Rating and Financial Key Figures

Ascendis Pharma Endocrinology Division A/S (CVR number: 32323537) is a company from GENTOFTE. The company reported a net sales of 122.9 mEUR in 2024, demonstrating a decline of -21.9 % compared to the previous year. The operating profit percentage was poor at -55.1 % (EBIT: -67.7 mEUR), while net earnings were -121.1 mEUR. The profitability of the company measured by Return on Assets (ROA) was -6.2 %, which can be considered poor and Return on Equity (ROE) was -190 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -97.3 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Ascendis Pharma Endocrinology Division A/S's liquidity measured by quick ratio was 0.2 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.